Literature DB >> 10594012

Auto-inhibition and partner proteins, core-binding factor beta (CBFbeta) and Ets-1, modulate DNA binding by CBFalpha2 (AML1).

T L Gu1, T L Goetz, B J Graves, N A Speck.   

Abstract

Core-binding factor alpha2 (CBFalpha2; otherwise known as AML1 or PEBP2alphaB) is a DNA-binding subunit in the family of core-binding factors (CBFs), heterodimeric transcription factors that play pivotal roles in multiple developmental processes in mammals, including hematopoiesis and bone development. The Runt domain in CBFalpha2 (amino acids 51 to 178) mediates DNA binding and heterodimerization with the non-DNA-binding CBFbeta subunit. Both the CBFbeta subunit and the DNA-binding protein Ets-1 stimulate DNA binding by the CBFalpha2 protein. Here we quantify and compare the extent of cooperativity between CBFalpha2, CBFbeta, and Ets-1. We also identify auto-inhibitory sequences within CBFalpha2 and sequences that modulate its interactions with CBFbeta and Ets-1. We show that sequences in the CBFalpha2 Runt domain and sequences C terminal to amino acid 214 inhibit DNA binding. Sequences C terminal to amino acid 214 also inhibit heterodimerization with the non-DNA-binding CBFbeta subunit, particularly heterodimerization off DNA. CBFbeta rescinds the intramolecular inhibition of CBFalpha2, stimulating DNA binding approximately 40-fold. In comparison, Ets-1 stimulates CBFalpha2 DNA binding 7- to 10-fold. Although the Runt domain alone is sufficient for heterodimerization with CBFbeta, sequences N terminal to amino acid 41 and between amino acids 190 and 214 are required for cooperative DNA binding with Ets-1. Cooperative DNA binding with Ets-1 is less pronounced with the CBFalpha2-CBFbeta heterodimer than with CBFalpha2 alone. These analyses demonstrate that CBFalpha2 is subject to both negative regulation by intramolecular interactions, and positive regulation by two alternative partnerships.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10594012      PMCID: PMC85059          DOI: 10.1128/MCB.20.1.91-103.2000

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  86 in total

1.  Interaction of murine ets-1 with GGA-binding sites establishes the ETS domain as a new DNA-binding motif.

Authors:  J A Nye; J M Petersen; C V Gunther; M D Jonsen; B J Graves
Journal:  Genes Dev       Date:  1992-06       Impact factor: 11.361

2.  Patterning of cells in the Drosophila eye by Lozenge, which shares homologous domains with AML1.

Authors:  A Daga; C A Karlovich; K Dumstrei; U Banerjee
Journal:  Genes Dev       Date:  1996-05-15       Impact factor: 11.361

3.  Absence of fetal liver hematopoiesis in mice deficient in transcriptional coactivator core binding factor beta.

Authors:  K Sasaki; H Yagi; R T Bronson; K Tominaga; T Matsunashi; K Deguchi; Y Tani; T Kishimoto; T Komori
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

4.  Modulation of transcription factor Ets-1 DNA binding: DNA-induced unfolding of an alpha helix.

Authors:  J M Petersen; J J Skalicky; L W Donaldson; L P McIntosh; T Alber; B J Graves
Journal:  Science       Date:  1995-09-29       Impact factor: 47.728

5.  Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor.

Authors:  S Wang; Q Wang; B E Crute; I N Melnikova; S R Keller; N A Speck
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

6.  AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.

Authors:  T Okuda; J van Deursen; S W Hiebert; G Grosveld; J R Downing
Journal:  Cell       Date:  1996-01-26       Impact factor: 41.582

7.  TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis.

Authors:  S A Shurtleff; A Buijs; F G Behm; J E Rubnitz; S C Raimondi; M L Hancock; G C Chan; C H Pui; G Grosveld; J R Downing
Journal:  Leukemia       Date:  1995-12       Impact factor: 11.528

8.  Genetics of a Drosophila phenoloxidase.

Authors:  T M Rizki; R M Rizki; R A Bellotti
Journal:  Mol Gen Genet       Date:  1985

9.  The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion.

Authors:  S P Romana; M Mauchauffé; M Le Coniat; I Chumakov; D Le Paslier; R Berger; O A Bernard
Journal:  Blood       Date:  1995-06-15       Impact factor: 22.113

10.  Cloning, mapping and expression of PEBP2 alpha C, a third gene encoding the mammalian Runt domain.

Authors:  S C Bae; E Takahashi; Y W Zhang; E Ogawa; K Shigesada; Y Namba; M Satake; Y Ito
Journal:  Gene       Date:  1995-07-04       Impact factor: 3.688

View more
  61 in total

1.  Phosphorylation represses Ets-1 DNA binding by reinforcing autoinhibition.

Authors:  D O Cowley; B J Graves
Journal:  Genes Dev       Date:  2000-02-01       Impact factor: 11.361

2.  Auto-inhibition of Ets-1 is counteracted by DNA binding cooperativity with core-binding factor alpha2.

Authors:  T L Goetz; T L Gu; N A Speck; B J Graves
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

3.  Activation of Mouse Tcrb: Uncoupling RUNX1 Function from Its Cooperative Binding with ETS1.

Authors:  Jiang-Yang Zhao; Oleg Osipovich; Olivia I Koues; Kinjal Majumder; Eugene M Oltz
Journal:  J Immunol       Date:  2017-06-21       Impact factor: 5.422

4.  Oct-1 counteracts autoinhibition of Runx2 DNA binding to form a novel Runx2/Oct-1 complex on the promoter of the mammary gland-specific gene beta-casein.

Authors:  Claire K Inman; Na Li; Paul Shore
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

Review 5.  Cytokines, Transcription Factors, and the Initiation of T-Cell Development.

Authors:  Hiroyuki Hosokawa; Ellen V Rothenberg
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-05-01       Impact factor: 10.005

Review 6.  Launching the T-cell-lineage developmental programme.

Authors:  Ellen V Rothenberg; Jonathan E Moore; Mary A Yui
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

7.  Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family.

Authors:  Peter C Hollenhorst; Atul A Shah; Christopher Hopkins; Barbara J Graves
Journal:  Genes Dev       Date:  2007-07-24       Impact factor: 11.361

8.  Tescalcin is an essential factor in megakaryocytic differentiation associated with Ets family gene expression.

Authors:  Konstantin Levay; Vladlen Z Slepak
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

9.  Small molecule inhibition of the CBFβ/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition.

Authors:  Anne L Carlton; Anuradha Illendula; Yan Gao; Danielle C Llaneza; Adam Boulton; Anant Shah; Roger A Rajewski; Charles N Landen; David Wotton; John H Bushweller
Journal:  Gynecol Oncol       Date:  2018-03-16       Impact factor: 5.482

10.  RUNX3 facilitates growth of Ewing sarcoma cells.

Authors:  Krista L Bledsoe; Meghan E McGee-Lawrence; Emily T Camilleri; Xiaoke Wang; Scott M Riester; Andre J van Wijnen; Andre M Oliveira; Jennifer J Westendorf
Journal:  J Cell Physiol       Date:  2014-12       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.